Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.

JTO Clin Res Rep · 2024 · PMC11420451 · PMID 39318388

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

This ratio at baseline was highly significant ( p < 0.0001) and was excellent to discriminate between responders (and prolonged PFS) and nonresponders (AUC = 1.0).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.